News:

This week IPhone 15 Pro winner is karn
You can be too a winner! Become the top poster of the week and win valuable prizes.  More details are You are not allowed to view links. Register or Login 

Main Menu

US regulators fast-track novel leukemia therapy

Started by riky, July 08, 2014, 09:00:23 AM

Previous topic - Next topic

0 Members and 1 Guest are viewing this topic.

riky

US regulators fast-track novel leukemia therapy

<p><a href="http://news.yahoo.com/us-regulators-fast-track-novel-leukemia-therapy-213503303.html"><img src="http://l.yimg.com/bt/api/res/1.2/Ck5XTUdteR66aMCc0PcICw--/YXBwaWQ9eW5ld3M7Zmk9ZmlsbDtoPTg2O3E9NzU7dz0xMzA-/http://media.zenfs.com/en_us/News/afp.com/ea588c489311fc30d0a763dec7c6b40445512090.jpg" width="130" height="86" alt="Nurses walk in a corridor on September 20, 2013 in a hospital in France" align="left" title="Nurses walk in a corridor on September 20, 2013 in a hospital in France" border="0" /></a>US regulators on Monday put an experimental immunotherapy agent on the fast track to market approval, after 89 percent of leukemia patients in early trials saw their cancers disappear. The personalized immunotherapy known as CTL019 was developed by the University of Pennsylvania and was designated a &quot;breakthrough therapy&quot; by the US Food and Drug Administration. It is the first cancer immunotherapy to receive the breakthrough designation, and only the fifth biologic agent so far. The approach works by extracting a patient's T-cells, then genetically programming them in the lab to target cancer cells that produce a protein called CD19.</p><br clear="all"/>

Source: You are not allowed to view links. Register or Login
You are not allowed to view links. Register or Login